News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Prologue Research International Announces New Company Appointments

11/9/2007 7:45:44 AM

Prologue is pleased to announce the arrival of our new Vice President of Clinical Operations, Robert A. Stude. Mr. Stude brings with him nearly 25 years of experience in the pharmaceutical industry, including over 15 years in the CRO realm. As VP of Clinical Operations, his roles will include overseeing the monitoring services, site services, and clinical services groups as well as interfacing with the Project Management and Business Development departments to both insure the quality, on-time progression of current studies and help secure new business opportunities for future trials.

Prior to joining Prologue, Mr. Stude held various positions at pharmaceutical and CRO companies, most recently as a Senior Director of Monitoring and Clinical Services for Integrium Cardiovascular Research and prior to that as Senior Director of Clinical Services for i3 Research. Prologue wholeheartedly welcomes him to the team and looks forward to his guidance as we continue to grow as ‘The Oncology CRO’.

Additionally, Prologue is excited to announce the promotion of Phillip L. Banks to Senior Vice President of Biostatistics and Data Management. Mr. Banks is an M.S. statistician who has designed and analyzed numerous cancer clinical trials during his nearly 25 years in the biostatistical/clinical research field. He is now responsible for overseeing the activities of the Biostatistics, Data Management, and Information Technology departments.

Mr. Banks’ expertise includes providing strategic leadership for the design and analysis of cancer clinical trials, development of data management and statistical analysis plans, writing of clinical protocols, interpretation of clinical data for reports and publications, and senior review of technical documents. In his tenure, he has received numerous awards including an FDA Citation for exemplary leadership on an NDA for AML cancer patients, election as Fellow (F.R.S.) of the Royal Stastistical Society in London, and is one of the few biostatisticians who is a member of American Society of Clinical Oncology (ASCO).

For more information about these appointments or to learn more about Prologue’s full range of oncology clinical trial services, please visit our website at or email

Read at

comments powered by Disqus